Polybia paulista is a species of social wasp found in Brazil. Its venom has been studied for potential medicinal properties, particularly its ability to stimulate the immune system. The venom contains a variety of peptides, enzymes, and other molecules that may act as antigens and elicit an immunological response. These include polybia-MP1, polybia-MP2, polybia-MP3, polybia-MP4, polybia-MP5, polybia-MP6, polybia-MP7, polybia-MP8, polybia-MP9, polybia-MP10, polybia-MP11, polybia-MP12, polybia-MP13, polybia-MP14, polybia-MP15, polybia-MP16, polybia-MP17, polybia-MP18, polybia-MP19, polybia-MP20, polybia-MP21, polybia-MP22, polybia-MP23, polybia-MP24, polybia-MP25, polybia-MP26, polybia-MP27, polybia-MP28, polybia-MP29, polybia-MP30, polybia-MP31, polybia-MP

The application of Polybia paulista cDNA and recombinant antigen can be in several areas, including:
Pain research: Polybia paulista venom contains a peptide known as MP1 (mastoparan-like peptide 1), which has been found to cause pain by activating the TRPV1 receptor. cDNA can be used to identify the gene that encodes MP1, and recombinant MP1 can be used to study its effects on pain and the underlying molecular mechanisms.
Antimicrobial research: Polybia paulista venom also contains several peptides that exhibit antimicrobial activity against bacteria and fungi. cDNA can be used to identify the genes that encode these peptides, and recombinant peptides can be produced for use in research on antimicrobial activity and mode of action.
Allergy research: Polybia paulista venom can cause allergic reactions in some individuals. cDNA and recombinant antigens can be used to identify the specific proteins in the venom that are responsible for the allergic response and to develop diagnostic tests for allergy.
Biotechnology: Polybia paulista venom peptides have potential applications in biotechnology, such as in the development of novel therapeutics, drug delivery systems, and imaging agents.

Overall, the use of Polybia paulista cDNA and recombinant antigen has great potential for advancing our understanding of pain, antimicrobial activity, allergies, and biotechnology. The venom of Polybia paulista contains a diverse range of bioactive molecules, which can be harnessed for various applications in research and industry.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.